SNFGE SNFGE
 
Thématique :
- Foie
Originalité :
Intermédiaire
Solidité :
Très solide
Doit faire évoluer notre pratique :
Immédiatement
 
 
Nom du veilleur :
Professeur Jean-Marie PERON
Coup de coeur :
 
 
Gastroenterology
  2016/12  
 
  2016 Dec;151(6):1046-1051  
  doi: 10.1053/j.gastro.2016.10.010  
 
  Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?  
 
  Chalasani N, Regev A  
  https://www.ncbi.nlm.nih.gov/pubmed/27765688  
 
 

Despite extensive research and considerable progress in recent decades, drug-induced liver injury (DILI) remains a major concern for patients, health care providers, and drug makers. Early prediction, diagnosis, and assessment of DILI during drug development continue to present major challenges to the drug industry, and hepatic safety concerns remain a leading cause for aborted development of new drugs. Presently, most drug makers rely during drug development on regulatory guidelines, position papers by various expert groups,3–6and consultation with external experts.

 
Question posée
 
Mise au point.
 
Question posée
 
Diagnostic et prise en charge de l’hépatotoxicité des médicaments chez les patients porteurs de cirrhose.
 
Commentaires

-

 
www.snfge.org